Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Capital Expenditures (2016 - 2025)

Immucell (ICCC) has disclosed Capital Expenditures for 16 consecutive years, with $593924.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 571.77% year-over-year to $593924.0, compared with a TTM value of $1.3 million through Sep 2025, down 37.74%, and an annual FY2024 reading of $465725.0, down 75.39% over the prior year.
  • Capital Expenditures was $593924.0 for Q3 2025 at Immucell, up from $155159.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.8 million in Q4 2023 and bottomed at -$1.3 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $527383.9, with a median of $675400.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures tumbled 273.7% in 2023, then soared 571.77% in 2025.
  • Year by year, Capital Expenditures stood at $704594.0 in 2021, then soared by 111.49% to $1.5 million in 2022, then grew by 19.27% to $1.8 million in 2023, then crashed by 88.96% to $196216.0 in 2024, then skyrocketed by 202.69% to $593924.0 in 2025.
  • Business Quant data shows Capital Expenditures for ICCC at $593924.0 in Q3 2025, $155159.0 in Q2 2025, and $329050.0 in Q1 2025.